Maverix Medical Closes Acquisition Of Cirrus Bio As Foundation For Diagnostics Platform In Lung Cancer

By Author: jamescolin
Total Articles: 215
Comment this article

Maverix Medical, a specialized platform dedicated to advancing lung cancer care, jointly established by Ajax Health, KKR, and Hologic, Inc., made headlines today with the acquisition of Cirrus Bio, a significant player in the field. The acquisition, finalized for an undisclosed sum, marks Maverix Medical's strategic move towards enhancing its diagnostic capabilities.

Cirrus Bio is renowned for its development and commercialization of multiomic solutions crucial for the early diagnosis and management of diseases. Led by industry veterans David Mallery (CEO) and Scott Morris (CSO), Cirrus Bio has a rich history of founding and leading successful ventures in the healthcare sector, including Molecular Profiling Institute, Paradigm Diagnostics, Viomics, and the International Genomics Consortium.

The acquisition of Cirrus Bio has paved the way for the establishment of a new division within Maverix Medical, aptly named Maverix Dx. This dedicated diagnostic division will focus on developing, investing in, acquiring, and commercializing a suite of cutting-edge diagnostic tools tailored specifically for lung cancer. David ...
... Mallery will helm Maverix Dx as the Chief Executive Officer, while Scott Morris assumes the role of Chief Scientific Officer, leveraging their expertise to drive innovation and strategic initiatives.

Duke Rohlen, Executive Chairman of Maverix Medical, emphasized the critical need for early detection in combating lung cancer, citing it as the primary motivation behind the acquisition. With Cirrus Bio's advanced technology and seasoned talent onboard, Maverix Medical aims to revolutionize lung cancer care by offering a comprehensive diagnostic portfolio.

In addition to the Cirrus Bio acquisition, Maverix Medical also introduced Serpex Medical, its first major product platform focusing on steerable technologies for precise lung tissue biopsy and therapy delivery. Led by Serpex founder and CEO Sasha Schrode, Serpex Medical will form the cornerstone of Maverix's medical device division, named Maverix Med Device.

David Mallery, CEO of Maverix Dx, expressed optimism about the prospects in the lung cancer market, highlighting the vast potential for innovation and collaboration. Maverix Medical, backed by financial sponsors KKR and Hologic, remains committed to investing in both developmental and commercial-stage lung cancer companies, with a keen interest in collaborating with industry leaders to advance lung cancer care.

https://www.techdogs.com/tech-news/pr-newswire/maverix-medical-closes-acquisition-of-cirrus-bio-as-foundation-for-diagnostics-platform-in-lung-cancer